Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

McGill University

$32,000.00

The multidrug resistance transporter (MDR1) of human malaria: elucidation of its critical function in malaria physiology and its contribution to the development of drug resistance

EF 2011-12

Résumé
Malaria remains a major infectious disease in many parts of the world, currently accounting for an estimated 5 billion clinical episodes and up to 3 million deaths annually. The human malaria parasite Plasmodium falciparum is a single-celled microorganism that invades human erythrocytes. The parasite has many developmental stages and is perfectly adapted to live in the human vertebrate. Drug resistance has emerged as a major problem in the treatment of all microbial agents and has proven to be a major obstacle for the prevention and treatment of malaria worldwide. In spite of our knowledge of transporters that mediate drug resistance in other systems (e.g. cancer cells) very little is known about their physiology and contribution to the development of drug resistance in P. falciparum malaria. Malaria parasites have a P-glycoprotein transporter (termed PfMDR1), encoded by the pfmdr1 gene. Several studies have shown that PfMDR1 is predominantly localized to the parasite's digestive vacuole, an acidic organelle where haemoglobin is degraded to supply the parasite with essential nutrients required for its survival. However, other reports suggest that PfMDR1 is also present in the plasma membrane of the parasite. The functional role of PfMDR1 and the substrate(s) transported by this transporter are unknown and the conflicting localisation studies have lead to confusion as to its contribution to drug resistance. One possibility is that the function of PfMDR1 is to clear toxins (and drugs) from the parasite cytosol by pumping them into the parasite's internal digestive vacuole and/or, in the case of any PfMDR1 on the parasite plasma membrane, out of the parasite. Using new technologies in live cell imaging we will elucidate the interactions of substances and drugs transported by PfMDR1. These studies are essential in preserving the efficacy of several very valuable anti-malaria drugs, and will also allow us to identify vital biochemical and physiological pathways of the parasite that we could exploit in future rational drug development programs.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
386409-2010
Name nom
Rohrbach, Petra
Department département
Parasitology, Institute of (Macdonald)
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2010
Award amount
32000
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5100
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell biology
Research subject fr
Biologie cellulaire
Partie
2
Nb partie
5
Application title
The multidrug resistance transporter (MDR1) of human malaria: elucidation of its critical function in malaria physiology and its contribution to the development of drug resistance
Keyword
NSERC
Application summary
Malaria remains a major infectious disease in many parts of the world, currently accounting for an estimated 5 billion clinical episodes and up to 3 million deaths annually. The human malaria parasite Plasmodium falciparum is a single-celled microorganism that invades human erythrocytes. The parasite has many developmental stages and is perfectly adapted to live in the human vertebrate. Drug resistance has emerged as a major problem in the treatment of all microbial agents and has proven to be a major obstacle for the prevention and treatment of malaria worldwide. In spite of our knowledge of transporters that mediate drug resistance in other systems (e.g. cancer cells) very little is known about their physiology and contribution to the development of drug resistance in P. falciparum malaria. Malaria parasites have a P-glycoprotein transporter (termed PfMDR1), encoded by the pfmdr1 gene. Several studies have shown that PfMDR1 is predominantly localized to the parasite's digestive vacuole, an acidic organelle where haemoglobin is degraded to supply the parasite with essential nutrients required for its survival. However, other reports suggest that PfMDR1 is also present in the plasma membrane of the parasite. The functional role of PfMDR1 and the substrate(s) transported by this transporter are unknown and the conflicting localisation studies have lead to confusion as to its contribution to drug resistance. One possibility is that the function of PfMDR1 is to clear toxins (and drugs) from the parasite cytosol by pumping them into the parasite's internal digestive vacuole and/or, in the case of any PfMDR1 on the parasite plasma membrane, out of the parasite. Using new technologies in live cell imaging we will elucidate the interactions of substances and drugs transported by PfMDR1. These studies are essential in preserving the efficacy of several very valuable anti-malaria drugs, and will also allow us to identify vital biochemical and physiological pathways of the parasite that we could exploit in future rational drug development programs.